Before we get started let’s review some facts regarding the proposed Livongo Teladoc merger and notice we said proposed merger as this is far from a done deal.
1. The Street hates this deal. The trading isn’t over yet but again today shares in both companies continue to sell off.
2. No one inside the diabetes community can believe Livongo pulled this off as they like us knew this house of cards would eventually collapse.
3. It’s beginning to dawn on people that Teladoc is vastly overpaying for Livongo.
Now here’s . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.